{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:47:27Z","timestamp":1761896847169},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shanghai Health and Family Planning Commission","award":["15GWZK0901"],"award-info":[{"award-number":["15GWZK0901"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40261-018-0706-5","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T13:54:30Z","timestamp":1537365270000},"page":"1167-1178","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review"],"prefix":"10.1007","volume":"38","author":[{"given":"Jie","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"issue":"10","key":"706_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255\u201368.","journal-title":"Leuk Res"},{"issue":"7081","key":"706_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/bmj.314.7081.657","volume":"314","author":"J Goldman","year":"1997","unstructured":"Goldman J. ABC of clinical haematology. Chronic myeloid leukaemia. BMJ. 1997;314(7081):657\u201360.","journal-title":"BMJ"},{"issue":"Suppl 2","key":"706_CR3","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M Hoglund","year":"2015","unstructured":"Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241\u20137.","journal-title":"Ann Hematol"},{"issue":"5","key":"706_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","volume":"36","author":"A Granatowicz","year":"2015","unstructured":"Granatowicz A, et al. An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med. 2015;36(5):197\u2013202.","journal-title":"Korean J Fam Med"},{"issue":"12","key":"706_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","volume":"14","author":"A Pallera","year":"2016","unstructured":"Pallera A, et al. NCCN guidelines insights: chronic myeloid leukemia, version 1.2017. J Natl Compr Cancer Netw. 2016;14(12):1505\u201312.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"706_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252\u201365.","journal-title":"Am J Hematol"},{"issue":"12","key":"706_CR7","first-page":"6355","volume":"35","author":"J Pinilla-Ibarz","year":"2015","unstructured":"Pinilla-Ibarz J, et al. Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Anticancer Res. 2015;35(12):6355\u201364.","journal-title":"Anticancer Res"},{"issue":"2","key":"706_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaoncol.2015.50","volume":"1","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C, Piazza R. Imatinib\u2014a new tyrosine kinase inhibitor for first-line treatment of chronic myeloid leukemia in 2015. JAMA Oncol. 2015;1(2):143\u20134.","journal-title":"JAMA Oncol"},{"issue":"9976","key":"706_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447\u201359.","journal-title":"Lancet"},{"issue":"5","key":"706_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","volume":"23","author":"K Dalziel","year":"2005","unstructured":"Dalziel K, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. 2005;23(5):515\u201326.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"706_CR11","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1002\/cncr.20694","volume":"101","author":"SD Reed","year":"2004","unstructured":"Reed SD, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101(11):2574\u201383.","journal-title":"Cancer"},{"issue":"7","key":"706_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-125-7-199610010-00002","volume":"125","author":"MW Kattan","year":"1996","unstructured":"Kattan MW, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996;125(7):541\u20138.","journal-title":"Ann Intern Med"},{"key":"706_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/2046-4053-3-54","volume":"3","author":"E Stovold","year":"2014","unstructured":"Stovold E, et al. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Syst Rev. 2014;3:54.","journal-title":"Syst Rev"},{"issue":"6","key":"706_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14737167.2016.1246960","volume":"16","author":"GA Mastrigt van","year":"2016","unstructured":"van Mastrigt GA, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689\u2013704.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"706_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S0266462313000160","volume":"29","author":"D Husereau","year":"2013","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29(2):117\u201322.","journal-title":"Int J Technol Assess Health Care"},{"issue":"05","key":"706_CR16","first-page":"442","volume":"18","author":"B Fangzhou","year":"2018","unstructured":"Fangzhou B, et al. Economic evaluation of liver cancer screening in China: a systematic review. Chin J Evid Based Med. 2018;18(05):442\u20139.","journal-title":"Chin J Evid Based Med"},{"issue":"1","key":"706_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","volume":"38","author":"N Li","year":"2018","unstructured":"Li N, et al. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China. Clin Drug Investig. 2018;38(1):79\u201386.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"706_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/13696998.2016.1261032","volume":"20","author":"N Li","year":"2017","unstructured":"Li N, et al. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. J Med Econ. 2017;20(4):328\u201336.","journal-title":"J Med Econ"},{"issue":"29","key":"706_CR19","doi-asserted-by":"publisher","first-page":"e7445","DOI":"10.1097\/MD.0000000000007445","volume":"96","author":"B Wu","year":"2017","unstructured":"Wu B, Liu M, Li T, Lin H, Zhong H. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: a CHEERS-compliant article. Medicine (Baltimore). 2017;96(29):e7445.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"706_CR20","doi-asserted-by":"publisher","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","volume":"108","author":"WV Padula","year":"2016","unstructured":"Padula WV, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"706_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3111\/13696998.2015.1126285","volume":"19","author":"J Whalen","year":"2016","unstructured":"Whalen J, et al. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. J Med Econ. 2016;19(5):445\u201361.","journal-title":"J Med Econ"},{"key":"706_CR22","doi-asserted-by":"publisher","first-page":"982395","DOI":"10.1155\/2015\/982395","volume":"2015","author":"U Rochau","year":"2015","unstructured":"Rochau U, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treat. 2015;2015:982395. \n                    https:\/\/doi.org\/10.1155\/2015\/982395\n                    \n                  .","journal-title":"Leuk Res Treat."},{"issue":"4","key":"706_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.clinthera.2014.02.008","volume":"36","author":"W Kulpeng","year":"2014","unstructured":"Kulpeng W, et al. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Ther. 2014;36(4):534\u201343.","journal-title":"Clin Ther"},{"issue":"8","key":"706_CR24","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3109\/10428194.2014.982635","volume":"56","author":"U Rochau","year":"2014","unstructured":"Rochau U, et al. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2014;56(8):2315\u201325.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"706_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7705\/biomedica.v34i1.1446","volume":"34","author":"M Romero","year":"2014","unstructured":"Romero M, et al. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica. 2014;34(1):48\u201359.","journal-title":"Biomedica"},{"issue":"8","key":"706_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","volume":"14","author":"M Hoyle","year":"2011","unstructured":"Hoyle M, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011;14(8):1057\u201367.","journal-title":"Value Health"},{"issue":"12","key":"706_CR27","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","volume":"26","author":"EQ Wu","year":"2010","unstructured":"Wu EQ, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"706_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/0284186X.2010.495132","volume":"49","author":"O Ghatnekar","year":"2010","unstructured":"Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib\u2014a Swedish model application. Acta Oncol. 2010;49(6):851\u20138.","journal-title":"Acta Oncol"},{"issue":"Suppl 3","key":"706_CR29","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1111\/j.1524-4733.2009.00635.x","volume":"12","author":"Z Chen","year":"2009","unstructured":"Chen Z, et al. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health. 2009;12(Suppl 3):S85\u20138.","journal-title":"Value Health"},{"issue":"5","key":"706_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00019053-200826050-00007","volume":"26","author":"SD Reed","year":"2008","unstructured":"Reed SD, et al. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics. 2008;26(5):435\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"706_CR31","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.clinthera.2004.11.007","volume":"26","author":"E Warren","year":"2004","unstructured":"Warren E, et al. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther. 2004;26(11):1924\u201333.","journal-title":"Clin Ther"},{"issue":"4","key":"706_CR32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/sj.bjc.6601151","volume":"89","author":"A Gordois","year":"2003","unstructured":"Gordois A, et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer. 2003;89(4):634\u201340.","journal-title":"Br J Cancer"},{"key":"706_CR33","first-page":"6","volume":"03","author":"L Guoen","year":"2011","unstructured":"Guoen L, Shanlian H, Jiuhong W. China guidelines for pharmacoeconomic evaluations (version 2011). China J Pharm Econ. 2011;03:6\u20139.","journal-title":"China J Pharm Econ"},{"issue":"10","key":"706_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"23","key":"706_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16230","volume":"16","author":"E Loveman","year":"2012","unstructured":"Loveman E, et al. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess. 2012;16(23):1\u2013137.","journal-title":"Health Technol Assess"},{"issue":"2","key":"706_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"6","key":"706_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/0962280211419832","volume":"24","author":"G Baio","year":"2015","unstructured":"Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. Stat Methods Med Res. 2015;24(6):615\u201334.","journal-title":"Stat Methods Med Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0706-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T23:26:44Z","timestamp":1568849204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0706-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0706-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"19 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by the Fourth Round of the Three-year Action Plan on Public Health Discipline and Talent Program (Evidence-based Public Health and Health Economics, No. 15GWZK0901) from the Shanghai Health and Family Planning Commission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflicts of interest to disclose regarding this study. We confirm that we have read the journal\u2019s position on issues covered by ethical publications and confirm that this report meets these guidelines. All the authors were substantially involved in the study and\/or preparation of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}